Gout Prevalence, Practice Patterns, and Associations with Outcomes in North American Dialysis Patients
Kidney360 · 2023-01 · 4 (1) · 54-62
DOI: 10.34067/kid.0005392022 ↗Kurz gefasst
Fachartikel in der Zeitschrift Kidney360, online erschienen am 05.12.2022. Verfasst von Murilo Guedes und 11 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Pontificia Universidade Catolica do Parana, Curitiba, Brazil. Hauptthemen laut MEDLINE: Allopurinol, Gout. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Horizon Therapeutics USA, Inc. Global.
Abstract (Originalsprache)
Key Points Gout is a common inflammatory arthropathy, and it can be as frequent in patients with ESKD as in the general adult population. Patient outcomes and providers' practice patterns for ESKD patients with gout are unknown. We sought to address these gaps in this study. We found that gout is not associated with worse clinical or patient-reported outcomes, despite being frequent and possibly under-reported.
Introduction
Gout occurs frequently in patients with kidney disease and can lead to a significant burden on quality of life. Gout prevalence, and its association with outcomes in hemodialysis (HD) and peritoneal dialysis (PD) populations located in North America, is unknown.
Methods
We used data from North America cohorts of 70,297 HD patients (DOPPS, 2012–2020) and 5117 PD patients (PDOPPS, 2014–2020). We used three definitions of gout for this analysis: ( 1 ) having an active prescription for colchicine or febuxostat; ( 2 ) having an active prescription for colchicine, febuxostat, or allopurinol; or ( 3 ) having an active prescription for colchicine, febuxostat, or allopurinol, or prior diagnosis of gout. Propensity score matching was used to compare outcomes among patients with versus without gout. Outcomes included erythropoietin resistance index (ERI=erythropoiesis stimulating agent dose per week/(hemoglobin×weight)), all-cause mortality, hospitalization, and patient-reported outcomes (PROs).
Results
The gout prevalence was 13% in HD and 21% in PD; it was highest among incident dialysis patients. Description of previous history of gout was rare, and identification of gout defined by colchicine (2%–3%) or febuxostat (1%) prescription was less frequent than by allopurinol (9%–12%). Both HD and PD patients with gout (versus no gout) were older, were more likely male, had higher body mass index, and had higher prevalence of cardiovascular comorbidities. About half of patients with a gout history were prescribed urate-lowering therapy. After propensity score matching, mean ERI was 3%–6% higher for gout versus non-gout patients while there was minimal evidence of association with clinical outcomes or PROs.
Conclusion
In a large cohort of PD and HD patients in North America, we found that gout occurs frequently and is likely under-reported. Gout was not associated with adverse clinical or PROs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Medicine, Pontificia Universidade Catolica do Parana, Curitiba, Brazil.
- Arbor Research Collaborative for Health, Ann Arbor, Michigan.
- Horizon Therapeutics, Deerfield, Illinois.
- Carolina Nephrology, PA, Greenville, South Carolina.
- Florida State University, Tallahassee, Florida.
- Division of Nephrology, Department of Medicine, University of Washington, Seattle, Washington.
Förderung
- Horizon Therapeutics USA, Inc. Global
Zitieren
APA
Guedes, M., Zhao, J., LaMoreaux, B., Marder, B., Gorlitsky, B., Domingues, V., Rivara, M. B., Lew, S., Robinson, B., Pecoits-Filho, R., Karaboyas, A., & DOPPS7 Country Investigators* (2023). Gout Prevalence, Practice Patterns, and Associations with Outcomes in North American Dialysis Patients. Kidney360, 4(1), 54-62. https://doi.org/10.34067/kid.0005392022
Vancouver
Guedes M, Zhao J, LaMoreaux B, Marder B, Gorlitsky B, Domingues V, et al. Gout Prevalence, Practice Patterns, and Associations with Outcomes in North American Dialysis Patients. Kidney360. 2023;4(1):54-62. doi:10.34067/kid.0005392022
BibTeX
@article{Guedes2023,
author = {Guedes, Murilo and Zhao, Junhui and LaMoreaux, Brian and Marder, Brad and Gorlitsky, Barry and Domingues, Vinicius and Rivara, Matthew B and Lew, Susie and Robinson, Bruce and Pecoits-Filho, Roberto and Karaboyas, Angelo and DOPPS7 Country Investigators*, DOPPS7 Country Investigators*},
title = {Gout Prevalence, Practice Patterns, and Associations with Outcomes in North American Dialysis Patients},
journal = {Kidney360},
year = {2023},
volume = {4},
number = {1},
pages = {54--62},
doi = {10.34067/kid.0005392022}
}
EUVIMED